Anticipated Program Milestones: ORIC anticipates the following upcoming data milestones: ORIC-114: 1H 2025: 2L EGFR exon 20 and 2L+ HER2 exon 20; 2H 2025: 2L+ EGFR atypical; 1H 2026: 1L EGFR exon 20; Mid-2026: 1L EGFR exon 20 combination with SC amivantamab and 1L EGFR atypical. ORIC-944: 4Q 2025 / 1H 2026: Combination with AR inhibitors. As of September 30, 2024, cash, cash equivalents and investments totaled $282.4 million, which the company expects will be sufficient to fund its operating plan into late 2026.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC: